Protaryx Medical Receives FDA 510(k) Clearance for Transseptal Puncture Device
核心洞察
Protaryx Medical (搜索) received FDA 510(k) clearance for its proprietary transseptal puncture device designed to facilitate safe left-heart access for cardiac interventions.
The device features zero-exchange delivery with an extendable positioning probe and radiofrequency guidewire technology compatible with standard electrosurgical generators.
Early clinical evaluation in a first-in-human study of five patients demonstrated 100% procedural success with no device-related adverse events.
Protaryx Medical (搜索), a Maryland-based company focused on minimally invasive left-heart interventional therapies, has received FDA 510(k) clearance for its proprietary transseptal puncture device. The approval represents a significant milestone for the company as it seeks to address critical challenges in safe and efficient transseptal access procedures.
Device Design and Technology
The Protaryx Transseptal Puncture Device is engineered to facilitate safe and reproducible left-heart access through innovative design features. The system offers zero-exchange delivery, incorporating a unique atraumatic design intended to reduce procedural steps and eliminate the need for rewiring during transseptal access.
Key technological features include a highly echogenic, extendable positioning probe and a radiofrequency (RF) guidewire compatible with standard electrosurgical generators. The device enables physicians to reach the left atrium (搜索) without needing to repeatedly change the catheter or sheath, streamlining the procedural workflow.
The system provides site-specific puncture capability to optimize access and positioning, aiming to reduce risks associated with suboptimal alignment, procedural complexity, and downstream complications.
Clinical Applications
Transseptal puncture is designed to enable access to the left side of the heart, allowing physicians to perform catheter-based treatments including atrial fibrillation (搜索) (AF) ablation, left atrial appendage (搜索) (LAA) closure, and mitral valve repair/replacement (TVMR or TEER).
Clinical Evidence
Early clinical evaluation in a first-in-human study demonstrated promising results. The study, which enrolled five patients, achieved procedural success in all cases. No device-related adverse events were reported, and the study showed minimal crossing time as well as reduced fluoroscopic exposure, providing evidence of workflow improvement and patient safety.
The first-in-human trial was completed in December 2024, with procedures conducted at Sanatorio Italiano hospital in Paraguay following approval from the Research Ethics Committee of the Paraguayan Institute of Social Studies.
Industry Impact
"Receiving FDA 510(k) clearance is a defining moment for Protaryx," said David Mester, CEO of Protaryx Medical (搜索). "This achievement reflects the dedication of our team to solving one of the most critical challenges in safe and efficient transseptal access procedures. We are now positioned to bring this transformative technology to physicians and patients across the US."
Dr. James Gammie, Protaryx co-founder and System Chief of Cardiac Surgery at Johns Hopkins, emphasized the technology's potential impact: "This clearance underscores the strength of the technology and its potential to set a new standard for transseptal puncture. By simplifying access to the left atrium (搜索), the device can expand procedural adoption while improving safety, precision, and ease-of-use."
Market Context
The approval comes as the global transcatheter heart valve replacement market is expected to reach $19.62 billion by 2026, with North America dominating the global market. This growth trajectory suggests significant commercial opportunities in the transcatheter devices market, though regulatory approval and procedural risks remain ongoing challenges.
Protaryx Medical (搜索) now plans to advance commercialization in the US and expand clinical adoption of its transseptal puncture technology.